IRVINE, CA / ACCESSWIRE / September 6, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel.
Josh Riggs, CEO of Oncocyte, will be meeting 1x1 with registered investors during the conference. The Company's virtual presentation will be available on demand starting September 11th at 7:00 a.m. ET at https://hcwevents.com/annualconference/
To request a meeting with Oncocyte, please contact your H.C. Wainwright representative or email the Company's investor relations team at This email address is being protected from spambots. You need JavaScript enabled to view it.
About Oncocyte
Oncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/
VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Stephanie Prince
PCG Advisory
(646) 863-6341
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.73 |
| Daily Volume: | 0 |
| Market Cap: | US$45.970M |
June 23, 2025 April 30, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
